Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 194

1.

Twelve years of pneumococcal conjugate vaccination in the Netherlands: Impact on incidence and clinical outcomes of invasive pneumococcal disease.

Vestjens SMT, Sanders EAM, Vlaminckx BJ, de Melker HE, van der Ende A, Knol MJ.

Vaccine. 2019 Sep 6. pii: S0264-410X(19)31075-8. doi: 10.1016/j.vaccine.2019.08.025. [Epub ahead of print]

PMID:
31500963
2.

Comparison of antibody response between boys and girls after infant and childhood vaccinations in the Netherlands.

Hoes J, Knol MJ, Mollema L, Buisman A, de Melker HE, van der Klis FRM.

Vaccine. 2019 Jul 26;37(32):4504-4510. doi: 10.1016/j.vaccine.2019.06.055. Epub 2019 Jul 4.

PMID:
31279563
3.

Third national biobank for population-based seroprevalence studies in the Netherlands, including the Caribbean Netherlands.

Verberk JDM, Vos RA, Mollema L, van Vliet J, van Weert JWM, de Melker HE, van der Klis FRM.

BMC Infect Dis. 2019 May 28;19(1):470. doi: 10.1186/s12879-019-4019-y.

4.

Risk of Measles and Diphtheria Introduction and Transmission on Bonaire, Caribbean Netherlands, 2018.

Vos RA, Mollema L, Kerkhof J, van den Kerkhof JHCT, Gerstenbluth I, Janga-Jansen AVA, Stienstra Y, de Melker HE, van der Klis FRM.

Am J Trop Med Hyg. 2019 Jul;101(1):237-241. doi: 10.4269/ajtmh.18-0824.

5.

Disease burden of varicella versus other vaccine-preventable diseases before introduction of vaccination into the national immunisation programme in the Netherlands.

van Lier A, de Gier B, McDonald SA, Mangen MJ, van Wijhe M, Sanders EAM, Kretzschmar ME, van Vliet H, de Melker HE.

Euro Surveill. 2019 May;24(18). doi: 10.2807/1560-7917.ES.2019.24.18.1800363.

6.

Cost-effectiveness of screening for chronic hepatitis B and C among migrant populations in a low endemic country.

Suijkerbuijk AWM, van Hoek AJ, Koopsen J, de Man RA, Mangen MJ, de Melker HE, Polder JJ, de Wit GA, Veldhuijzen IK.

PLoS One. 2018 Nov 8;13(11):e0207037. doi: 10.1371/journal.pone.0207037. eCollection 2018.

7.

Persistence of immune response following bivalent HPV vaccination: A follow-up study among girls routinely vaccinated with a two-dose schedule.

Schurink-van 't Klooster TM, Donken R, Schepp RM, van der Klis FRM, de Melker HE.

Vaccine. 2018 Nov 26;36(49):7580-7587. doi: 10.1016/j.vaccine.2018.10.018. Epub 2018 Oct 28.

8.

Systematically Developing a Web-Based Tailored Intervention Promoting HPV-Vaccination Acceptability Among Mothers of Invited Girls Using Intervention Mapping.

Pot M, Ruiter RAC, Paulussen TWGM, Heuvelink A, de Melker HE, van Vliet HJA, van Keulen HM.

Front Public Health. 2018 Sep 28;6:226. doi: 10.3389/fpubh.2018.00226. eCollection 2018.

9.

[Quantifying the impact of mass vaccination programmes on notified cases in the Netherlands].

Tulen AD, van Wijhe M, Korthals Altes H, McDonald SA, de Melker HE, Postma MJ, Wallinga J.

Ned Tijdschr Geneeskd. 2018 Sep 20;162. pii: D2983. Dutch.

PMID:
30306758
10.

No evidence found for an increased risk of long-term fatigue following human papillomavirus vaccination of adolescent girls.

Schurink-Van't Klooster TM, Kemmeren JM, van der Maas NAT, van de Putte EM, Ter Wolbeek M, Nijhof SL, Vanrolleghem AM, van Vliet JA, Sturkenboom M, de Melker HE.

Vaccine. 2018 Oct 29;36(45):6796-6802. doi: 10.1016/j.vaccine.2018.09.019. Epub 2018 Sep 24.

11.

Updated cost-effectiveness and risk-benefit analysis of two infant rotavirus vaccination strategies in a high-income, low-endemic setting.

Bruijning-Verhagen P, van Dongen JAP, Verberk JDM, Pijnacker R, van Gaalen RD, Klinkenberg D, de Melker HE, Mangen MJ.

BMC Med. 2018 Sep 10;16(1):168. doi: 10.1186/s12916-018-1134-3.

12.

Socioeconomic Status Is Associated With Antibody Levels Against Vaccine Preventable Diseases in the Netherlands.

Hoes J, Boef AGC, Knol MJ, de Melker HE, Mollema L, van der Klis FRM, Rots NY, van Baarle D.

Front Public Health. 2018 Jul 27;6:209. doi: 10.3389/fpubh.2018.00209. eCollection 2018.

13.

Changes in (risk) behavior and HPV knowledge among Dutch girls eligible for HPV vaccination: an observational cohort study.

Donken R, Tami A, Knol MJ, Lubbers K, van der Sande MAB, Nijman HW, Daemen T, Weijmar Schultz WCM, de Melker HE.

BMC Public Health. 2018 Jul 5;18(1):837. doi: 10.1186/s12889-018-5745-6.

14.

Effectiveness of the DTPa-HBV-IPV/Hib vaccine against invasive Haemophilus influenzae type b disease in the Netherlands (2003-16): a case-control study.

Monge S, Hahné SJ, de Melker HE, Sanders EA, van der Ende A, Knol MJ.

Lancet Infect Dis. 2018 Jul;18(7):749-757. doi: 10.1016/S1473-3099(18)30166-X. Epub 2018 May 8.

PMID:
29752131
15.

Implementation of MenACWY vaccination because of ongoing increase in serogroup W invasive meningococcal disease, the Netherlands, 2018.

Knol MJ, Ruijs WL, Antonise-Kamp L, de Melker HE, van der Ende A.

Euro Surveill. 2018 Apr;23(16). doi: 10.2807/1560-7917.ES.2018.23.16.18-00158.

16.

Quantifying the impact of mass vaccination programmes on notified cases in the Netherlands.

van Wijhe M, Tulen AD, Korthals Altes H, McDonald SA, de Melker HE, Postma MJ, Wallinga J.

Epidemiol Infect. 2018 Apr;146(6):716-722. doi: 10.1017/S0950268818000481. Epub 2018 Mar 14.

PMID:
29534768
17.

High Effectiveness of the Bivalent Human Papillomavirus (HPV) Vaccine Against Incident and Persistent HPV Infections up to 6 Years After Vaccination in Young Dutch Women.

Donken R, King AJ, Bogaards JA, Woestenberg PJ, Meijer CJLM, de Melker HE.

J Infect Dis. 2018 Apr 23;217(10):1579-1589. doi: 10.1093/infdis/jiy067.

PMID:
29409034
18.

Healthcare costs attributable to congenital cytomegalovirus infection.

Korndewal MJ, Weltevrede M, van den Akker-van Marle ME, Oudesluys-Murphy AM, de Melker HE, Vossen ACTM.

Arch Dis Child. 2018 May;103(5):452-457. doi: 10.1136/archdischild-2017-312805. Epub 2018 Jan 23.

PMID:
29363491
19.

Biennial Pattern of Rotavirus Gastroenteritis in The Netherlands and a Shifting Age Distribution After a Low Rotavirus Season, 2010-2016.

Verberk JDM, Pijnacker R, Bruijning-Verhagen P, Franz E, Vennema H, Hooiveld M, Hahné SJM, de Melker HE.

Pediatr Infect Dis J. 2018 Sep;37(9):e248-e250. doi: 10.1097/INF.0000000000001880.

PMID:
29278607
20.

Temporal associations between national outbreaks of meningococcal serogroup W and C disease in the Netherlands and England: an observational cohort study.

Knol MJ, Hahné SJM, Lucidarme J, Campbell H, de Melker HE, Gray SJ, Borrow R, Ladhani SN, Ramsay ME, van der Ende A.

Lancet Public Health. 2017 Oct;2(10):e473-e482. doi: 10.1016/S2468-2667(17)30157-3. Epub 2017 Aug 24.

21.

Differences by sex in IgG levels following infant and childhood vaccinations: An individual participant data meta-analysis of vaccination studies.

Boef AGC, van der Klis FRM, Berbers GAM, Buisman AM, Sanders EAM, Kemmeren JM, van der Ende A, de Melker HE, Rots NY, Knol MJ.

Vaccine. 2018 Jan 8;36(3):400-407. doi: 10.1016/j.vaccine.2017.11.070. Epub 2017 Dec 6.

PMID:
29223483
22.

Intention to vaccinate universally against varicella, rotavirus gastroenteritis, meningococcal B disease and seasonal influenza among parents in the Netherlands: an internet survey.

van Lier A, Ferreira JA, Mollema L, Sanders EAM, de Melker HE.

BMC Res Notes. 2017 Dec 4;10(1):672. doi: 10.1186/s13104-017-3004-z.

23.

Impact of infant pneumococcal conjugate vaccination on community acquired pneumonia hospitalization in all ages in the Netherlands.

van Deursen AMM, Schurink-Van't Klooster TM, Man WH, van de Kassteele J, van Gageldonk-Lafeber AB, Bruijning-Verhagen PCJL, de Melker HE, Sanders EAM, Knol MJ.

Vaccine. 2017 Dec 18;35(51):7107-7113. doi: 10.1016/j.vaccine.2017.10.090. Epub 2017 Nov 13.

PMID:
29146381
24.

Bivalent Vaccine Effectiveness Against Type-Specific HPV Positivity: Evidence for Cross-Protection Against Oncogenic Types Among Dutch STI Clinic Visitors.

Woestenberg PJ, King AJ, van Benthem BHB, Donken R, Leussink S, van der Klis FRM, de Melker HE, van der Sande MAB, Hoebe CJPA, Bogaards JA; Medical Microbiological Laboratories and the Public Health Services.

J Infect Dis. 2018 Jan 4;217(2):213-222. doi: 10.1093/infdis/jix582.

25.

Estimating the Population-Level Effectiveness of Vaccination Programs in the Netherlands.

van Wijhe M, McDonald SA, de Melker HE, Postma MJ, Wallinga J.

Epidemiology. 2018 Mar;29(2):215-223. doi: 10.1097/EDE.0000000000000778.

PMID:
29087989
26.

Long-term impairment attributable to congenital cytomegalovirus infection: a retrospective cohort study.

Korndewal MJ, Oudesluys-Murphy AM, Kroes ACM, van der Sande MAB, de Melker HE, Vossen ACTM.

Dev Med Child Neurol. 2017 Dec;59(12):1261-1268. doi: 10.1111/dmcn.13556. Epub 2017 Oct 9.

27.

Infectious reactivation of cytomegalovirus explaining age- and sex-specific patterns of seroprevalence.

van Boven M, van de Kassteele J, Korndewal MJ, van Dorp CH, Kretzschmar M, van der Klis F, de Melker HE, Vossen AC, van Baarle D.

PLoS Comput Biol. 2017 Sep 26;13(9):e1005719. doi: 10.1371/journal.pcbi.1005719. eCollection 2017 Sep. Erratum in: PLoS Comput Biol. 2019 Jun 12;15(6):e1007146.

28.

A novel measles outbreak control strategy in the Netherlands in 2013-2014 using a national electronic immunization register: A study of early MMR uptake and its determinants.

Nic Lochlainn LM, Woudenberg T, van Lier A, Zonnenberg I, Philippi M, de Melker HE, Hahné SJM.

Vaccine. 2017 Oct 13;35(43):5828-5834. doi: 10.1016/j.vaccine.2017.09.018. Epub 2017 Sep 18.

29.

Effectiveness of a Web-Based Tailored Intervention With Virtual Assistants Promoting the Acceptability of HPV Vaccination Among Mothers of Invited Girls: Randomized Controlled Trial.

Pot M, Paulussen TG, Ruiter RA, Eekhout I, de Melker HE, Spoelstra ME, van Keulen HM.

J Med Internet Res. 2017 Sep 6;19(9):e312. doi: 10.2196/jmir.7449.

30.

Non-specific effects of measles, mumps, and rubella (MMR) vaccination in high income setting: population based cohort study in the Netherlands.

Tielemans SMAJ, de Melker HE, Hahné SJM, Boef AGC, van der Klis FRM, Sanders EAM, van der Sande MAB, Knol MJ.

BMJ. 2017 Aug 30;358:j3862. doi: 10.1136/bmj.j3862.

31.

Informed decision making in the context of childhood immunization.

Lehmann BA, de Melker HE, Timmermans DRM, Mollema L.

Patient Educ Couns. 2017 Dec;100(12):2339-2345. doi: 10.1016/j.pec.2017.06.015. Epub 2017 Jun 26.

32.

Baseline incidence of intussusception in early childhood before rotavirus vaccine introduction, the Netherlands, January 2008 to December 2012.

Gadroen K, Kemmeren JM, Bruijning-Verhagen PC, Straus SM, Weibel D, de Melker HE, Sturkenboom MC.

Euro Surveill. 2017 Jun 22;22(25). pii: 30556. doi: 10.2807/1560-7917.ES.2017.22.25.30556.

33.

Severe underestimation of pertussis related hospitalizations and deaths in the Netherlands: A capture-recapture analysis.

van der Maas NAT, Hoes J, Sanders EAM, de Melker HE.

Vaccine. 2017 Jul 24;35(33):4162-4166. doi: 10.1016/j.vaccine.2017.06.037. Epub 2017 Jun 23.

PMID:
28651837
34.

Congenital Cytomegalovirus Infection: Child Development, Quality of Life and Impact on Daily Life.

Korndewal MJ, Oudesluys-Murphy AM, Kroes ACM, Vossen ACTM, de Melker HE.

Pediatr Infect Dis J. 2017 Dec;36(12):1141-1147. doi: 10.1097/INF.0000000000001663.

PMID:
28650934
35.

The intention of Dutch general practitioners to offer vaccination against pneumococcal disease, herpes zoster and pertussis to people aged 60 years and older.

Lehmann BA, Eilers R, Mollema L, Ferreira J, de Melker HE.

BMC Geriatr. 2017 Jun 7;17(1):122. doi: 10.1186/s12877-017-0511-7.

36.

Elevated Immune Response Among Children 4 Years of Age With Pronounced Local Adverse Events After the Fifth Diphtheria, Tetanus, Acellular Pertussis Vaccination.

van der Lee S, Kemmeren JM, de Rond LGH, Öztürk K, Westerhof A, de Melker HE, Sanders EAM, Berbers GAM, van der Maas NAT, Rümke HC, Buisman AM.

Pediatr Infect Dis J. 2017 Sep;36(9):e223-e229. doi: 10.1097/INF.0000000000001620.

PMID:
28430750
37.

Dutch national immunization schedule: compliance and associated characteristics for the primary series.

Scheepers ED, van Lier A, Drijfhout IH, Berbers G, van der Maas NAT, de Melker HE, Knol MJ.

Eur J Pediatr. 2017 Jun;176(6):769-778. doi: 10.1007/s00431-017-2904-1. Epub 2017 Apr 20.

PMID:
28429116
38.

Comparison of the tolerability of newly introduced childhood vaccines in the Netherlands.

Kemmeren JM, van der Maas NA, de Melker HE.

Eur J Pediatr. 2017 Jun;176(6):757-768. doi: 10.1007/s00431-017-2901-4. Epub 2017 Apr 20.

PMID:
28429115
39.

Vaccine preferences and acceptance of older adults.

Eilers R, de Melker HE, Veldwijk J, Krabbe PFM.

Vaccine. 2017 May 15;35(21):2823-2830. doi: 10.1016/j.vaccine.2017.04.014. Epub 2017 Apr 12.

40.

Sex differences in invasive pneumococcal disease and the impact of pneumococcal conjugate vaccination in the Netherlands, 2004 to 2015.

Wagenvoort GH, Sanders EA, Vlaminckx BJ, de Melker HE, van der Ende A, Knol MJ.

Euro Surveill. 2017 Mar 9;22(10). pii: 30481. doi: 10.2807/1560-7917.ES.2017.22.10.30481.

41.

Long-term mortality after IPD and bacteremic versus non-bacteremic pneumococcal pneumonia.

Wagenvoort GH, Sanders EA, de Melker HE, van der Ende A, Vlaminckx BJ, Knol MJ.

Vaccine. 2017 Mar 27;35(14):1749-1757. doi: 10.1016/j.vaccine.2017.02.037. Epub 2017 Mar 3.

PMID:
28262334
42.

A longitudinal study on determinants of HPV vaccination uptake in parents/guardians from different ethnic backgrounds in Amsterdam, the Netherlands.

Alberts CJ, van der Loeff MF, Hazeveld Y, de Melker HE, van der Wal MF, Nielen A, El Fakiri F, Prins M, Paulussen TG.

BMC Public Health. 2017 Feb 21;17(1):220. doi: 10.1186/s12889-017-4091-4.

43.

Disease burden of human papillomavirus infection in the Netherlands, 1989-2014: the gap between females and males is diminishing.

McDonald SA, Qendri V, Berkhof J, de Melker HE, Bogaards JA.

Cancer Causes Control. 2017 Mar;28(3):203-214. doi: 10.1007/s10552-017-0870-6. Epub 2017 Feb 17.

PMID:
28213874
44.

Large measles epidemic in the Netherlands, May 2013 to March 2014: changing epidemiology.

Woudenberg T, van Binnendijk RS, Sanders EA, Wallinga J, de Melker HE, Ruijs WL, Hahné SJ.

Euro Surveill. 2017 Jan 19;22(3). pii: 30443. doi: 10.2807/1560-7917.ES.2017.22.3.30443.

45.

Immune Responses After 2 Versus 3 Doses of HPV Vaccination up to 4½ Years After Vaccination: An Observational Study Among Dutch Routinely Vaccinated Girls.

Donken R, Schurink-Van't Klooster TM, Schepp RM, van der Klis FR, Knol MJ, Meijer CJ, de Melker HE.

J Infect Dis. 2017 Feb 1;215(3):359-367. doi: 10.1093/infdis/jiw588.

PMID:
28011916
46.

The whole story: a systematic review of economic evaluations of HPV vaccination including non-cervical HPV-associated diseases.

Suijkerbuijk AW, Donken R, Lugnér AK, de Wit GA, Meijer CJ, de Melker HE, Bogaards JA.

Expert Rev Vaccines. 2017 Apr;16(4):361-375. doi: 10.1080/14760584.2017.1256778. Epub 2016 Nov 24. Review.

PMID:
27807989
47.

Performance of a bedside test for tetanus immunity: results of a cross-sectional study among three EDs in the Netherlands in 2012-2013.

van der Maas NA, Donken R, Te Wierik MJ, Swaan CM, Hahne SJ, de Melker HE.

Emerg Med J. 2016 Nov;33(11):763-768. doi: 10.1136/emermed-2015-205412. Epub 2016 Sep 8.

PMID:
27609502
48.

[Infection prevention in newborns through maternal vaccination: current insights and developments].

van der Maas NA, van Aerde K, Bont LJ, Bekker MN, Rots N, de Melker HE.

Ned Tijdschr Geneeskd. 2016;160:D411. Dutch.

PMID:
27507412
49.

Herpes simplex virus type 1 and type 2 in the Netherlands: seroprevalence, risk factors and changes during a 12-year period.

Woestenberg PJ, Tjhie JH, de Melker HE, van der Klis FR, van Bergen JE, van der Sande MA, van Benthem BH.

BMC Infect Dis. 2016 Aug 2;16:364. doi: 10.1186/s12879-016-1707-8.

50.

Mumps-specific cross-neutralization by MMR vaccine-induced antibodies predicts protection against mumps virus infection.

Gouma S, Ten Hulscher HI, Schurink-van 't Klooster TM, de Melker HE, Boland GJ, Kaaijk P, van Els CACM, Koopmans MPG, van Binnendijk RS.

Vaccine. 2016 Jul 29;34(35):4166-4171. doi: 10.1016/j.vaccine.2016.06.063. Epub 2016 Jun 29.

PMID:
27372154

Supplemental Content

Loading ...
Support Center